期刊文献+

万古霉素联合多黏菌素B用药对肾小管上皮细胞的作用 被引量:1

Effect of vancomycin combined with polymyxin B on the viability of renal tubular epithelial cells
原文传递
导出
摘要 目的研究万古霉素和多黏菌素B联合用药对肾小管上皮细胞(HK2)活力的影响。方法搭建并验证多黏菌素B的人体生理药代动力学(PBPK)模型。基于模型预测万古霉素、多黏菌素B在人体肾脏、肾小管中的组织分布特征。四唑氮氢氧化物法(XTT)检测万古霉素低剂量组(0.5 mg/mL)、万古霉素高剂量组(2.0mg/mL)、多黏菌素组(50 mg/mL)、万古霉素低剂量+多黏菌素组、万古霉素高剂量+多黏菌素组分别对HK2细胞活力及细胞线粒体超氧化物生成的影响。结果建立并验证多黏菌素B PBPK模型,建立及验证的模型所预测的PK参数值与实测PK参数比值均在0.81.2之间。预测多黏菌素B静脉滴注给药后肾脏和肾小管浓度均高于血浆浓度,肾小管药物浓度约为血浆的10倍。肾脏、肾小管药物达峰时间明显滞后,其中肾小管浓度达峰时间为5.3 h,浓度高于50μg/mL的持续时间为8.5 h。细胞活力实验结果显示,8和24 h后万古霉素低剂量组、万古霉素高剂量组、多黏菌素B组、万古霉素低剂量+多黏菌素B组、万古霉素高剂量+多黏菌素B组细胞增殖抑制率分别为1.73%、4.77%、10.34%、10.54%和11.76%及1.95%、7.46%、11.27%、11.55%和16.49%。其中,只有万古霉素高剂量+多黏菌素B组的HK2细胞8 h后产生有统计学意义的线粒体超氧化物。结论万古霉素与多黏菌素B的联合使用可增加肾小管毒性,特别是高剂量万古霉素合用多黏菌素B促使细胞产生线粒体超氧化物。 Objective To investigate the effect of vancomycin combined with polymyxin B on the viability of human renal tubular epithelial cells(HK2).Methods We developed and validated a physiologically based pharmacokinetic model(PBPK)of polymyxin B(PMB).Tissue distribution of vancomycin(VAN)and PMB in the renal tubule and kidney was predicted based on the PBPK model.The effects of VAN and/or PMB[low dose VAN group(0.5 mg/mL),high dose VAN group(2 mg/mL),PMB group(50 μg/mL),low dose VAN + PMB group,high dose VAN + PMB group]on the vitality of HK2 cells and mitochondrial superoxide production were detected by XTT assay.The production of mitochondrial superoxide in HK2 cells was detected by MitoSox.Results The PBPK model of PMB in human was established and validated.The ratio of predicted PK parameters and the observed PK parameters was in the range of 0.8~1.2.It was predicted that the concentration of PMB in the kidney and renal tubules was higher than that in plasma,and the concentration in renal tubules was about 10 times higher than that in plasma.Tmaxof PMB in kidney and renal tubules were significantly delayed.The Tmaxin renal tubules was about 5.3 h,and the duration of concentration higher than 50 μg/mL in renal tubules was 8.5 h.The results of cell viability assay showed that the inhibition rates of cell proliferation in low dose VAN group,high dose VAN group,PMB group,low dose VAN + PMB group,high dose VAN + PMB group were 1.73%,4.77%,10.34%,10.54%,11.76% after 8 h,and 1.95%,7.46%,11.27%,11.55%,and 16.49% after 24 h,respectively.Among them,only the high dose VAN + PMB group produced statistically significant mitochondrial superoxide in HK2 cells.Conclusion The combination of VAN and PMB can increase the toxicity of renal tubules.In particular,high-dose VAN(2.0 mg/mL)+ PMB(50 μg/mL)can promote the production of mitochondrial superoxide in cells.
作者 杜海燕 卢静 王基平 谭莉 刘文芳 石秀锦 林佰弟 赵莉敏 庄笑梅 韩美灵 林阳 DU Hai-yan;LU Jing;WANG Ji-ping;TAN Li;LIU Wen-fang;SHI Xiu-jin;LIN Bai-di;ZHAO Li-min;ZHUANG Xiao-mei;HAN Mei-Ling;LIN Yang(Department of Pharnmacy,Beijing Anzhen Hospial,Capital Medical Universty,Beijing 100029,Chin;Biomedicine Disconery hatite,Deparimen of Microbiology,Monash Uniovensity,Clayton VIC 3800,Autralia;Bejing hnstiute of Heart Lung and Blood VesselDiseases,Beijing Arzhen Hopial,Capital Medical University,Beijing 100029,China;State Key Laboratory of Toxicology and Medical Counerneasure hnsitue of Pharmacogy and Toxicalogy,Beijing 100850,China)
出处 《临床药物治疗杂志》 2021年第1期39-44,共6页 Clinical Medication Journal
基金 国家科技重大专项项目(2017ZX09304017) 国家科技重大专项项目(2018ZX0971103006)。
关键词 生理药代动力学模型 万古霉素 多黏菌素B 组织分布 肾毒性 physiologically based pharmacokinetic(PBPK)model vancomycin(VAN) polymyxin B(PMB) tissue distribution nephrotoxicity
  • 相关文献

参考文献2

二级参考文献70

  • 1Cruickshank JM. Beta-blockers and heart failure. Indian Heart J 2010; 62: 101-10.
  • 2de Groote P, Ennezat PV, Mouquet F. Bisoprolol in the treatment of chronic heart failure. Vasc Health Risk Manag 2007; 3: 431-9.
  • 3McGavin JK, Keating GM. Bisoprolol: a review of its use in chronic heart failure. Drugs 2002; 62:2677 -96.
  • 4Papadopulos DP, Papademetriou V. Low-dose fixed combination of bisoprolol/hydrochlorothiazide as first line for hypertension: a review of the rationale and clinical evidence. Angiology 2009; 60: 601-7.
  • 5CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
  • 6Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray J J, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-8.
  • 7Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 2010; 12: 974-82.
  • 8Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, etal. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341-62.
  • 9Brophy KM, Scariett-Ferguson H, Webber KS. Clinical drug therapy for Canadian practice. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2010.
  • 10Kirch W, Rose I, Demers HG, Leopold G, Pabst J, Ohnhaus EE. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet 1987; 13: 110-7.

共引文献19

同被引文献13

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部